This review summarizes the role of multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy (BTRE). The study highlights the complex etiology of BTRE, which involves genetic, molecular, and environmental factors. Advances in multi-omics technologies, including genomics, transcriptomics, epigenomics, proteomics, and metabolomics, have enabled the identification of molecular biomarkers and pathophysiological mechanisms underlying BTRE. Genomic studies have identified key genes such as BRAF and IDH variants that are associated with BTRE. Transcriptomic analyses have revealed the role of miRNAs and lncRNAs in BTRE development. Epigenomic studies have shown that DNA methylation and histone modifications are involved in the regulation of gene expression in BTRE. Proteomic studies have identified proteins such as AQP-4 and Cx43 that are associated with seizure occurrence and epileptogenesis. Metabolomic studies have indicated that the PI3K/AKT/mTOR pathway and glutamate metabolism are involved in BTRE development. The study also discusses the challenges and opportunities in the diagnosis and treatment of BTRE. It emphasizes the importance of integrating multi-omics approaches to better understand the molecular mechanisms of BTRE and develop targeted therapies. The review concludes that further research is needed to explore the role of epigenetic biomarkers and to improve the early diagnosis and treatment of BTRE. The findings suggest that a comprehensive understanding of the molecular and genetic factors involved in BTRE is essential for developing effective therapeutic strategies.This review summarizes the role of multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy (BTRE). The study highlights the complex etiology of BTRE, which involves genetic, molecular, and environmental factors. Advances in multi-omics technologies, including genomics, transcriptomics, epigenomics, proteomics, and metabolomics, have enabled the identification of molecular biomarkers and pathophysiological mechanisms underlying BTRE. Genomic studies have identified key genes such as BRAF and IDH variants that are associated with BTRE. Transcriptomic analyses have revealed the role of miRNAs and lncRNAs in BTRE development. Epigenomic studies have shown that DNA methylation and histone modifications are involved in the regulation of gene expression in BTRE. Proteomic studies have identified proteins such as AQP-4 and Cx43 that are associated with seizure occurrence and epileptogenesis. Metabolomic studies have indicated that the PI3K/AKT/mTOR pathway and glutamate metabolism are involved in BTRE development. The study also discusses the challenges and opportunities in the diagnosis and treatment of BTRE. It emphasizes the importance of integrating multi-omics approaches to better understand the molecular mechanisms of BTRE and develop targeted therapies. The review concludes that further research is needed to explore the role of epigenetic biomarkers and to improve the early diagnosis and treatment of BTRE. The findings suggest that a comprehensive understanding of the molecular and genetic factors involved in BTRE is essential for developing effective therapeutic strategies.